Content Navigation
( All
None )
| Target and Pathway |
Top |
| Target(s) |
Glycogen synthase kinase-3 alpha (GSK-3A) |
Target Info
|
Modulator |
[3], [4] |
| Glycogen synthase kinase-3 beta (GSK-3B) |
Target Info
|
Modulator |
[3], [4] |
| References |
Top |
| REF 1 |
URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7958).
|
| REF 2 |
ClinicalTrials.gov (NCT01214603) A Study in Participants With Acute Leukemia. U.S. National Institutes of Health.
|
| REF 3 |
Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
|
| REF 4 |
Activating the Wnt/beta-Catenin Pathway for the Treatment of Melanoma--Application of LY2090314, a Novel Selective Inhibitor of Glycogen Synthase Kinase-3. PLoS One. 2015 Apr 27;10(4):e0125028.
|
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.
